{"transactions":[{"id":768647,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-05-21T20:06:49.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":34200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027."},{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 20, 2027."}],"balance_after":34200,"derivative":{"underlying":"Common Stock","underlying_shares":34200},"source":{"system":"sec-edgar","filing":"0001741836-26-000005","document":"wk-form4_1779394006.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000174183626000005/wk-form4_1779394006.xml","form_type":"4"}},{"id":768646,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2026-05-21T20:06:49.000Z","date":"2026-05-20","kind":"grant","planned":false,"acquired":true,"shares":41800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options to vest 100% on May 20, 2027."}],"balance_after":41800,"derivative":{"exercise_price":1.23,"expiration_date":"2036-05-20","underlying":"Common Stock","underlying_shares":41800},"source":{"system":"sec-edgar","filing":"0001741836-26-000005","document":"wk-form4_1779394006.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000174183626000005/wk-form4_1779394006.xml","form_type":"4"}},{"id":776698,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2026-05-15T21:46:18.000Z","date":"2026-05-15","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 100% of the award on the earlier of (a) the date of the next annual meeting of the Issuer's stockholders and (b) May 15, 2027, in each case, subject to the Reporting Person's provision of service to the Issuer on such vesting date."}],"balance_after":31250,"derivative":{"exercise_price":15.86,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":31250},"source":{"system":"sec-edgar","filing":"0001741836-26-000004","document":"wk-form4_1778881574.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000174183626000004/wk-form4_1778881574.xml","form_type":"4"}},{"id":945584,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-07T01:00:26.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":6065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026."}],"balance_after":6065,"derivative":{"exercise_price":7.08,"expiration_date":"2036-01-02","underlying":"Ordinary Shares","underlying_shares":6065},"source":{"system":"sec-edgar","filing":"0001741836-26-000002","document":"form4-01062026_080112.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741836/000174183626000002/form4-01062026_080112.xml","form_type":"4"}},{"id":945583,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-01-07T01:00:26.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":3032,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted share unit (\"RSU\") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."}],"balance_after":15532,"source":{"system":"sec-edgar","filing":"0001741836-26-000002","document":"form4-01062026_080112.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741836/000174183626000002/form4-01062026_080112.xml","form_type":"4"}},{"id":1003457,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2025-11-10T12:19:00.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning December 6, 2025 until the option is fully vested on November 6, 2028, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":12.52,"expiration_date":"2035-11-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001741836-25-000009","document":"wk-form4_1762777138.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1549595/000174183625000009/wk-form4_1762777138.xml","form_type":"4"}},{"id":1043711,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-09-10T20:52:19.000Z","date":"2025-09-08","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option will vest in three equal installments on each of September 8, 2026, September 8, 2027 and September 8, 2028."}],"balance_after":25000,"derivative":{"exercise_price":7.16,"expiration_date":"2035-09-08","underlying":"Ordinary Shares","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001415889-25-024098","document":"form4-09102025_080916.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741836/000141588925024098/form4-09102025_080916.xml","form_type":"4"}},{"id":1043710,"issuer":{"id":5993,"kind":"organization","name":"BICYCLE THERAPEUTICS PLC","symbol":"BCYC"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-09-10T20:52:19.000Z","date":"2025-09-08","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents a restricted share unit (\"RSU\") award. The RSUs will vest in three equal installments on each of September 8, 2026, September 8, 2027 and September 8, 2028."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represents a contingent right to receive one ordinary share."}],"balance_after":12500,"source":{"system":"sec-edgar","filing":"0001415889-25-024098","document":"form4-09102025_080916.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741836/000141588925024098/form4-09102025_080916.xml","form_type":"4"}},{"id":1104551,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:13.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-25-017826","document":"form4-06202025_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017826/form4-06202025_040609.xml","form_type":"4"}},{"id":1104550,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:13.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5868},"source":{"system":"sec-edgar","filing":"0001415889-25-017826","document":"form4-06202025_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017826/form4-06202025_040609.xml","form_type":"4"}},{"id":1104549,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T16:15:13.000Z","date":"2025-06-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the \"Issuer\"), Concentra Biosciences, LLC (\"Parent\") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a \"Share\") for an offer price of (i) $0.57 per Share in cash (the \"Cash Amount\"), and (ii) one non-transferable contractual contingent value right (each, a \"CVR\"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the \"CVR Agreement\"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the \"Offer Price\").[continues to Footnote 2]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"[continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\"). As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an \"Option\") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger [continues to Footnote 3]"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"[continues from Footnote 2] and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":1.28,"expiration_date":"2033-04-19","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001415889-25-017826","document":"form4-06202025_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588925017826/form4-06202025_040609.xml","form_type":"4"}},{"id":1139360,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-05-21T20:57:32.000Z","date":"2025-05-21","kind":"exercise","planned":false,"acquired":false,"shares":2167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2167},"source":{"system":"sec-edgar","filing":"0001055726-25-000034","document":"wk-form4_1747861045.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000034/wk-form4_1747861045.xml","form_type":"4"}},{"id":1139359,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-21T20:57:32.000Z","date":"2025-05-21","kind":"exercise","planned":false,"acquired":true,"shares":2167,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 21, 2025."}],"balance_after":8916,"source":{"system":"sec-edgar","filing":"0001055726-25-000034","document":"wk-form4_1747861045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572625000034/wk-form4_1747861045.xml","form_type":"4"}},{"id":1468564,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-26T16:36:41.000Z","date":"2024-06-25","kind":"grant","planned":false,"acquired":true,"shares":34000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":34000,"derivative":{"exercise_price":0.95,"expiration_date":"2034-06-24","underlying":"Common Stock","underlying_shares":34000},"source":{"system":"sec-edgar","filing":"0001415889-24-018238","document":"form4-06262024_080638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000141588924018238/form4-06262024_080638.xml","form_type":"4"}},{"id":1505959,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-22T20:49:53.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":2167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units will vest 100% on May 21, 2025."}],"balance_after":2167,"derivative":{"underlying":"Common Stock","underlying_shares":2167},"source":{"system":"sec-edgar","filing":"0001055726-24-000035","document":"wk-form4_1716410983.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000035/wk-form4_1716410983.xml","form_type":"4"}},{"id":1505958,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2024-05-22T20:49:53.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":2917,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This grant was made under the 2023 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Options to vest 100% on May 21, 2025."}],"balance_after":2917,"derivative":{"exercise_price":10.99,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":2917},"source":{"system":"sec-edgar","filing":"0001055726-24-000035","document":"wk-form4_1716410983.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000035/wk-form4_1716410983.xml","form_type":"4"}},{"id":1514752,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-16T21:00:35.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":false,"shares":2166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units vested 100% on May 15, 2024."},{"field":"shares","element":"transactionShares","label":"F2","text":"Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units vested 100% on May 15, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units vested 100% on May 15, 2024."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2166},"source":{"system":"sec-edgar","filing":"0001055726-24-000025","document":"wk-form4_1715893221.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000025/wk-form4_1715893221.xml","form_type":"4"}},{"id":1514751,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-16T21:00:35.000Z","date":"2024-05-15","kind":"exercise","planned":false,"acquired":true,"shares":2166,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units vested 100% on May 15, 2024."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024."}],"balance_after":6749,"source":{"system":"sec-edgar","filing":"0001055726-24-000025","document":"wk-form4_1715893221.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000025/wk-form4_1715893221.xml","form_type":"4"}},{"id":1519499,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2024-05-13T21:56:11.000Z","date":"2024-05-13","kind":"exercise","planned":false,"acquired":false,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 3,000 restricted stock units was as follows: 1,000 shares vested on May 13, 2022; 1,000 shares vested on May 13, 2023; and 1,000 shares vested on May 13, 2024.  Vested restricted stock units could be settled in shares of common stock, cash or a combination of both."},{"field":"shares","element":"transactionShares","label":"F2","text":"Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 3,000 restricted stock units was as follows: 1,000 shares vested on May 13, 2022; 1,000 shares vested on May 13, 2023; and 1,000 shares vested on May 13, 2024.  Vested restricted stock units could be settled in shares of common stock, cash or a combination of both."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 3,000 restricted stock units was as follows: 1,000 shares vested on May 13, 2022; 1,000 shares vested on May 13, 2023; and 1,000 shares vested on May 13, 2024.  Vested restricted stock units could be settled in shares of common stock, cash or a combination of both."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001055726-24-000023","document":"wk-form4_1715637359.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000023/wk-form4_1715637359.xml","form_type":"4"}},{"id":1519498,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-13T21:56:11.000Z","date":"2024-05-13","kind":"exercise","planned":false,"acquired":true,"shares":1000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 3,000 restricted stock units was as follows: 1,000 shares vested on May 13, 2022; 1,000 shares vested on May 13, 2023; and 1,000 shares vested on May 13, 2024.  Vested restricted stock units could be settled in shares of common stock, cash or a combination of both."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Gives effect to a 1-for-12 reverse stock split effected by the Issuer on January 24, 2024."}],"balance_after":4583,"source":{"system":"sec-edgar","filing":"0001055726-24-000023","document":"wk-form4_1715637359.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572624000023/wk-form4_1715637359.xml","form_type":"4"}},{"id":1709853,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5149,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":5149},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709852,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8582,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":8582},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709851,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3432,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a \"Company August 2023 PSU\") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":3432},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709850,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1827,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding \"Company Products PSU\" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding \"Company Products PSU\" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding \"Company Products PSU\" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding \"Company Products PSU\" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1827},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709849,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13279,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding \"Company Products PSU\" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding \"Company Products PSU\" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding \"Company Products PSU\" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding \"Company Products PSU\" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":13279},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709848,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4980,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":4980},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709847,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2575,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2575},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709846,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4291,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":4291},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709845,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41174,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":41174},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709844,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":16547,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":16547},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709843,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10184,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":10184},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709842,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1717,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1717},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709841,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":11900,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":11900},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709840,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Performance Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4756,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a \"Company PSU\"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":4756},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709839,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25747,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":25747},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709838,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2260,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a \"Post-Signing Company RSU\") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":2260},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709837,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":33468,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":33468},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709836,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":8586,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":8586},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709835,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Restricted Stock Units","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3298,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a \"Company RSU\"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":3298},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709834,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":154000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":137.96,"expiration_date":"2032-11-09","underlying":"Common stock","underlying_shares":154000},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709833,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":41250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":155.87,"expiration_date":"2031-08-16","underlying":"Common stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709832,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":642,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":155.87,"expiration_date":"2031-08-16","underlying":"Common stock","underlying_shares":642},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709831,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32073,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":161.82,"expiration_date":"2030-08-17","underlying":"Common stock","underlying_shares":32073},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709830,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":636,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":161.82,"expiration_date":"2030-08-17","underlying":"Common stock","underlying_shares":636},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709829,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18083,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":72.64,"expiration_date":"2029-08-30","underlying":"Common stock","underlying_shares":18083},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709828,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1333,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":72.64,"expiration_date":"2029-08-30","underlying":"Common stock","underlying_shares":1333},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709827,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Stock Options (Right to Buy)","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6140,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option."}],"balance_after":0,"derivative":{"exercise_price":65.11,"expiration_date":"2028-06-15","underlying":"Common stock","underlying_shares":6140},"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1709826,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-12-15T18:10:33.000Z","date":"2023-12-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":38338,"price":229,"value":8779402.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects the disposition of shares of common stock, par value $0.001 per share (\"Common Stock\"), of Seagen Inc. (\"Issuer\"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the \"Merger Agreement\"), by and among the Issuer, Pfizer Inc. (\"Parent\") and Aris Merger Sub, Inc. (\"Merger Sub\"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the \"Merger Consideration\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-23-070861","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000095017023070861/ownership.xml","form_type":"4"}},{"id":1774908,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-09-22T19:51:39.000Z","date":"2023-09-21","kind":"sale","planned":false,"acquired":false,"shares":71,"price":206.5,"value":14661.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/4/2021 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":116677,"source":{"system":"sec-edgar","filing":"0001203311-23-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000119/edgardoc.xml","form_type":"4"}},{"id":1774907,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-09-22T19:51:39.000Z","date":"2023-04-05","kind":"grant","planned":false,"acquired":true,"shares":3320,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares represent restricted stock units and will be settled in common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F2","text":"The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 1/15/2024, subject to continuous service with the Company until the vesting date"}],"balance_after":104702,"source":{"system":"sec-edgar","filing":"0001203311-23-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000119/edgardoc.xml","form_type":"4"}},{"id":1774906,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-09-22T19:51:39.000Z","date":"2023-03-13","kind":"grant","planned":false,"acquired":true,"shares":1660,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares represent restricted stock units and will be settled in common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F2","text":"The performance criteria for these restricted stock units were met. These restricted stock units will become fully vested on 1/15/2024, subject to continuous service with the Company until the vesting date"}],"balance_after":98513,"source":{"system":"sec-edgar","filing":"0001203311-23-000119","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000119/edgardoc.xml","form_type":"4"}},{"id":1791222,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-09-01T16:51:57.000Z","date":"2023-08-31","kind":"sale","planned":false,"acquired":false,"shares":4029,"price":206.9659,"value":833865.6111,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/24/2019 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":111768,"source":{"system":"sec-edgar","filing":"0001203311-23-000107","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000107/edgardoc.xml","form_type":"4"}},{"id":1793324,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-08-30T19:08:39.000Z","date":"2023-08-29","kind":"sale","planned":false,"acquired":false,"shares":1016,"price":206,"value":209296.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/13/2020 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":115797,"source":{"system":"sec-edgar","filing":"0001203311-23-000097","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000097/edgardoc.xml","form_type":"4"}},{"id":1793323,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-08-30T19:08:39.000Z","date":"2023-08-28","kind":"grant","planned":false,"acquired":true,"shares":1872,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The performance criteria for these restricted stock units were met. These restricted stock units became fully vested on 8/28/2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":116813,"source":{"system":"sec-edgar","filing":"0001203311-23-000097","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000097/edgardoc.xml","form_type":"4"}},{"id":1804217,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-08-17T20:59:46.000Z","date":"2023-08-16","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":2348,"price":193.8689,"value":455204.1772,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F6","text":"The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/4/2021 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 57 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on July 31, 2023."}],"balance_after":114941,"source":{"system":"sec-edgar","filing":"0001203311-23-000078","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000078/edgardoc.xml","form_type":"4"}},{"id":1804216,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-08-17T20:59:46.000Z","date":"2023-08-16","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":6100,"price":193.8689,"value":1182600.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The sales reported in this Form 4 were effected pursuant to a written plan adopted on 9/8/2022 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 57 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on July 31, 2023."}],"balance_after":117289,"source":{"system":"sec-edgar","filing":"0001203311-23-000078","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000078/edgardoc.xml","form_type":"4"}},{"id":1804215,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-08-17T20:59:46.000Z","date":"2023-08-16","kind":"disposition_to_issuer","planned":true,"acquired":false,"shares":1804,"price":193.8689,"value":349739.4956,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a written plan adopted on 11/13/2020 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 57 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on July 31, 2023."}],"balance_after":123389,"source":{"system":"sec-edgar","filing":"0001203311-23-000078","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000078/edgardoc.xml","form_type":"4"}},{"id":1804214,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-08-17T20:59:46.000Z","date":"2023-08-15","kind":"grant","planned":true,"acquired":true,"shares":25747,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These shares represent restricted stock units and will be settled in common stock upon vesting. 50% of the reporting person's annual equity award was granted in the form of performance stock units, which are not reflected here, and will be treated the same as these restricted stock units in the event the transaction with Pfizer\ncloses."},{"field":"date","element":"transactionDate","label":"F2","text":"Shares shall vest at a rate of 25% on each anniversary of August 15, 2023 until all shares are fully vested at the end of four years."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 57 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on July 31, 2023."}],"balance_after":125193,"source":{"system":"sec-edgar","filing":"0001203311-23-000078","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000078/edgardoc.xml","form_type":"4"}},{"id":1843996,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-26T16:14:57.000Z","date":"2023-06-22","kind":"grant","planned":false,"acquired":true,"shares":5868,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders."}],"balance_after":5868,"derivative":{"exercise_price":1.48,"expiration_date":"2033-06-21","underlying":"Common Stock","underlying_shares":5868},"source":{"system":"sec-edgar","filing":"0001209191-23-039695","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919123039695/doc4.xml","form_type":"4"}},{"id":1892065,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-05-16T20:48:47.000Z","date":"2023-05-16","kind":"exercise","planned":false,"acquired":false,"shares":19000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19000},"source":{"system":"sec-edgar","filing":"0001055726-23-000033","document":"wk-form4_1684270114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000033/wk-form4_1684270114.xml","form_type":"4"}},{"id":1892064,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-05-16T20:48:47.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest 100% on May 15, 2024."},{"field":"shares","element":"transactionShares","label":"F3","text":"This grant was made  under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest 100% on May 15, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. The restricted stock units will vest 100% on May 15, 2024."}],"balance_after":26000,"derivative":{"underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001055726-23-000033","document":"wk-form4_1684270114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000033/wk-form4_1684270114.xml","form_type":"4"}},{"id":1892063,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Options","published_at":"2023-05-16T20:48:47.000Z","date":"2023-05-15","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This grant was made  under the 2016 Omnibus Incentive Plan pursuant to the issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options to vest 100% on May 15, 2024."}],"balance_after":35000,"derivative":{"exercise_price":0.77,"expiration_date":"2033-05-15","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001055726-23-000033","document":"wk-form4_1684270114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000033/wk-form4_1684270114.xml","form_type":"4"}},{"id":1892062,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-05-16T20:48:47.000Z","date":"2023-05-13","kind":"exercise","planned":false,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 36,000 restricted stock units is as follows: 12,000 shares vested on May 13, 2022; 12,000 shares vested on May 13, 2023; 12,000 shares will vest on May 13, 2024.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 36,000 restricted stock units is as follows: 12,000 shares vested on May 13, 2022; 12,000 shares vested on May 13, 2023; 12,000 shares will vest on May 13, 2024.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 36,000 restricted stock units is as follows: 12,000 shares vested on May 13, 2022; 12,000 shares vested on May 13, 2023; 12,000 shares will vest on May 13, 2024.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."}],"balance_after":12000,"derivative":{"underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001055726-23-000033","document":"wk-form4_1684270114.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000033/wk-form4_1684270114.xml","form_type":"4"}},{"id":1892061,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-16T20:48:47.000Z","date":"2023-05-16","kind":"exercise","planned":false,"acquired":true,"shares":19000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of common stock. These restricted stock units vested 100% on May 16, 2023."}],"balance_after":43000,"source":{"system":"sec-edgar","filing":"0001055726-23-000033","document":"wk-form4_1684270114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000033/wk-form4_1684270114.xml","form_type":"4"}},{"id":1892060,"issuer":{"id":6589,"kind":"organization","name":"INOVIO PHARMACEUTICALS, INC."},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-16T20:48:47.000Z","date":"2023-05-13","kind":"exercise","planned":false,"acquired":true,"shares":12000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock.  The vesting schedule for the 36,000 restricted stock units is as follows: 12,000 shares vested on May 13, 2022; 12,000 shares vested on May 13, 2023; 12,000 shares will vest on May 13, 2024.  Vested restricted stock units can be settled in shares of common stock, cash or a combination of both."}],"balance_after":24000,"source":{"system":"sec-edgar","filing":"0001055726-23-000033","document":"wk-form4_1684270114.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1055726/000105572623000033/wk-form4_1684270114.xml","form_type":"4"}},{"id":1914716,"issuer":{"id":78257,"kind":"organization","name":"Kronos Bio, Inc.","symbol":"KRON"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-04-24T16:22:40.000Z","date":"2023-04-20","kind":"grant","planned":false,"acquired":true,"shares":68000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in three equal annual installments following the date of grant."}],"balance_after":68000,"derivative":{"exercise_price":1.28,"expiration_date":"2033-04-19","underlying":"Common Stock","underlying_shares":68000},"source":{"system":"sec-edgar","filing":"0001209191-23-025386","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1741830/000120919123025386/doc4.xml","form_type":"4"}},{"id":1917490,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-04-19T18:14:42.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vested at a rate of 25% on 8/30/2020. The remainder shall vest monthly until all the options are vested on 8/30/23."}],"balance_after":18083,"derivative":{"exercise_price":72.64,"expiration_date":"2029-08-30","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001203311-23-000041","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000041/edgardoc.xml","form_type":"4"}},{"id":1917489,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-04-19T18:14:42.000Z","date":"2023-04-17","kind":"sale","planned":true,"acquired":false,"shares":10000,"price":205.9488,"value":2059488.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a written plan adopted on September 9, 2022 that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $205.66 to $206.35. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":99389,"source":{"system":"sec-edgar","filing":"0001203311-23-000041","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000041/edgardoc.xml","form_type":"4"}},{"id":1917488,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-04-19T18:14:42.000Z","date":"2023-04-17","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":72.64,"value":726400.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":109389,"source":{"system":"sec-edgar","filing":"0001203311-23-000041","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000041/edgardoc.xml","form_type":"4"}},{"id":1923176,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-04-07T19:28:44.000Z","date":"2023-04-06","kind":"sale","planned":false,"acquired":false,"shares":333,"price":205.8566,"value":68550.2478,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":99389,"source":{"system":"sec-edgar","filing":"0001203311-23-000034","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000034/edgardoc.xml","form_type":"4"}},{"id":1923175,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-04-07T19:28:44.000Z","date":"2023-04-05","kind":"grant","planned":false,"acquired":true,"shares":609,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The performance criteria for these restricted stock units were met. These restricted stock units became fully vested on 4/5/2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":99722,"source":{"system":"sec-edgar","filing":"0001203311-23-000034","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000034/edgardoc.xml","form_type":"4"}},{"id":1929632,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-04-04T21:03:48.000Z","date":"2023-04-01","kind":"grant","planned":false,"acquired":true,"shares":2260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These restricted stock units will be settled in common stock upon vesting."},{"field":"shares","element":"transactionShares","label":"F2","text":"The restricted stock units shall vest 37.5% on the 18 month anniversary of the grant date, 31.25% on the 24 month anniversary of the grant date, and 31.25%\non the 30 month anniversary of the grant date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":99113,"source":{"system":"sec-edgar","filing":"0000899243-23-010594","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924323010594/doc4.xml","form_type":"4"}},{"id":1948121,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-03-17T16:20:43.000Z","date":"2023-03-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vested at a rate of 25% on 8/30/2020. The remainder shall vest monthly until all the options are vested on 8/30/23."}],"balance_after":28083,"derivative":{"exercise_price":72.64,"expiration_date":"2029-08-30","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-23-008871","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924323008871/doc4.xml","form_type":"4"}},{"id":1948120,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-03-17T16:20:43.000Z","date":"2023-03-15","kind":"sale","acquired":false,"shares":10000,"price":199.8115,"value":1998115.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $199.38 to $200.26. The price reported reflects the weighted average sale price.\nThe Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full\ninformation regarding the number of shares and prices at which the sales were effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":96853,"source":{"system":"sec-edgar","filing":"0000899243-23-008871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924323008871/doc4.xml","form_type":"4"}},{"id":1948119,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-03-17T16:20:43.000Z","date":"2023-03-15","kind":"exercise","acquired":true,"shares":10000,"price":72.64,"value":726400.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":106853,"source":{"system":"sec-edgar","filing":"0000899243-23-008871","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924323008871/doc4.xml","form_type":"4"}},{"id":2008686,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2023-02-17T16:23:47.000Z","date":"2023-02-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Options vested at a rate of 25% on 8/30/2020. The remainder shall vest monthly until all the options are vested on 8/30/2023."}],"balance_after":38083,"derivative":{"exercise_price":72.64,"expiration_date":"2029-08-30","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-23-005471","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924323005471/doc4.xml","form_type":"4"}},{"id":2008685,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-02-17T16:23:47.000Z","date":"2023-02-15","kind":"sale","acquired":false,"shares":2615,"price":141.04,"value":368819.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $140.88 to $141.45. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":96853,"source":{"system":"sec-edgar","filing":"0000899243-23-005471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924323005471/doc4.xml","form_type":"4"}},{"id":2008684,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-02-17T16:23:47.000Z","date":"2023-02-15","kind":"sale","acquired":false,"shares":7185,"price":140.55,"value":1009851.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Reflects sales of common stock executed in multiple transactions at prices ranging from $139.87 to $140.86. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":99468,"source":{"system":"sec-edgar","filing":"0000899243-23-005471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924323005471/doc4.xml","form_type":"4"}},{"id":2008683,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-02-17T16:23:47.000Z","date":"2023-02-15","kind":"sale","acquired":false,"shares":200,"price":138.62,"value":27724.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":106653,"source":{"system":"sec-edgar","filing":"0000899243-23-005471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924323005471/doc4.xml","form_type":"4"}},{"id":2008682,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-02-17T16:23:47.000Z","date":"2023-02-15","kind":"exercise","acquired":true,"shares":10000,"price":72.64,"value":726400.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":106853,"source":{"system":"sec-edgar","filing":"0000899243-23-005471","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924323005471/doc4.xml","form_type":"4"}},{"id":2033827,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-02-03T20:01:47.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":783,"price":138.52,"value":108461.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a 10b5-1 arrangement to satisfy tax obligations arising out of the vesting of previously granted restricted stock units."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting and 97 shares acquired under the Amended and Restated 2000 Employee Stock Purchase Plan on January 31, 2023."}],"balance_after":96853,"source":{"system":"sec-edgar","filing":"0001203311-23-000012","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000012/edgardoc.xml","form_type":"4"}},{"id":2045406,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-26T19:41:37.000Z","date":"2023-01-24","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vested at a rate of 25% on 8/30/2020. The remainder shall vest monthly until all the options are vested on 8/30/23."}],"balance_after":48083,"derivative":{"exercise_price":72.64,"expiration_date":"2029-08-30","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001203311-23-000010","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000010/edgardoc.xml","form_type":"4"}},{"id":2045405,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-01-26T19:41:37.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":10000,"price":135,"value":1350000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":97539,"source":{"system":"sec-edgar","filing":"0001203311-23-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000010/edgardoc.xml","form_type":"4"}},{"id":2045404,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, R&D & CMO"}}],"security":"Common Stock","published_at":"2023-01-26T19:41:37.000Z","date":"2023-01-24","kind":"exercise","acquired":true,"shares":10000,"price":72.64,"value":726400.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":107539,"source":{"system":"sec-edgar","filing":"0001203311-23-000010","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000010/edgardoc.xml","form_type":"4"}},{"id":2060893,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President R&D & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-06T19:10:07.000Z","date":"2023-01-05","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vested at a rate of 25% on 8/30/2020, The remainder shall vest monthly until all the options are vested on 8/30/23."}],"balance_after":58083,"derivative":{"exercise_price":72.64,"expiration_date":"2029-08-30","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001203311-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000004/edgardoc.xml","form_type":"4"}},{"id":2060892,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President R&D & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2023-01-06T19:10:07.000Z","date":"2023-01-04","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vested at a rate of 25% on 8/30/2020, The remainder shall vest monthly until all the options are vested on 8/30/23."}],"balance_after":65583,"derivative":{"exercise_price":72.64,"expiration_date":"2029-08-30","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001203311-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000004/edgardoc.xml","form_type":"4"}},{"id":2060891,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President R&D & CMO"}}],"security":"Common Stock","published_at":"2023-01-06T19:10:07.000Z","date":"2023-01-05","kind":"sale","acquired":false,"shares":7500,"price":135,"value":1012500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":97539,"source":{"system":"sec-edgar","filing":"0001203311-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000004/edgardoc.xml","form_type":"4"}},{"id":2060890,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President R&D & CMO"}}],"security":"Common Stock","published_at":"2023-01-06T19:10:07.000Z","date":"2023-01-05","kind":"exercise","acquired":true,"shares":7500,"price":72.64,"value":544800.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":105039,"source":{"system":"sec-edgar","filing":"0001203311-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000004/edgardoc.xml","form_type":"4"}},{"id":2060889,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President R&D & CMO"}}],"security":"Common Stock","published_at":"2023-01-06T19:10:07.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":2500,"price":135,"value":337500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":97539,"source":{"system":"sec-edgar","filing":"0001203311-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000004/edgardoc.xml","form_type":"4"}},{"id":2060888,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President R&D & CMO"}}],"security":"Common Stock","published_at":"2023-01-06T19:10:07.000Z","date":"2023-01-04","kind":"exercise","acquired":true,"shares":2500,"price":72.64,"value":181600.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":100039,"source":{"system":"sec-edgar","filing":"0001203311-23-000004","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331123000004/edgardoc.xml","form_type":"4"}},{"id":2084160,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research and Develo"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-16T19:42:11.000Z","date":"2022-12-14","kind":"exercise","acquired":false,"shares":9403,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vested at a rate of 25% on 8/30/2019 and monthly thereafter until all the options were fully vested on 8/30/22."}],"balance_after":0,"derivative":{"exercise_price":77.45,"expiration_date":"2028-09-07","underlying":"Common Stock","underlying_shares":9403},"source":{"system":"sec-edgar","filing":"0001203311-22-000067","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000067/edgardoc.xml","form_type":"4"}},{"id":2084159,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research and Develo"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-12-16T19:42:11.000Z","date":"2022-12-14","kind":"exercise","acquired":false,"shares":597,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vested at a rate of 25% on 8/30/2020. The remainder shall vest monthly until all the options are vested on 8/30/2023."}],"balance_after":68083,"derivative":{"exercise_price":72.64,"expiration_date":"2029-08-30","underlying":"Common Stock","underlying_shares":597},"source":{"system":"sec-edgar","filing":"0001203311-22-000067","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000067/edgardoc.xml","form_type":"4"}},{"id":2084158,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research and Develo"}}],"security":"Common Stock","published_at":"2022-12-16T19:42:11.000Z","date":"2022-12-14","kind":"sale","acquired":false,"shares":9403,"price":135,"value":1269405.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":97539,"source":{"system":"sec-edgar","filing":"0001203311-22-000067","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000067/edgardoc.xml","form_type":"4"}},{"id":2084157,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research and Develo"}}],"security":"Common Stock","published_at":"2022-12-16T19:42:11.000Z","date":"2022-12-14","kind":"exercise","acquired":true,"shares":9403,"price":77.45,"value":728262.35,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":106942,"source":{"system":"sec-edgar","filing":"0001203311-22-000067","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000067/edgardoc.xml","form_type":"4"}},{"id":2084156,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research and Develo"}}],"security":"Common Stock","published_at":"2022-12-16T19:42:11.000Z","date":"2022-12-14","kind":"sale","acquired":false,"shares":597,"price":135,"value":80595.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":97539,"source":{"system":"sec-edgar","filing":"0001203311-22-000067","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000067/edgardoc.xml","form_type":"4"}},{"id":2084155,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Research and Develo"}}],"security":"Common Stock","published_at":"2022-12-16T19:42:11.000Z","date":"2022-12-14","kind":"exercise","acquired":true,"shares":597,"price":72.64,"value":43366.08,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting."}],"balance_after":98136,"source":{"system":"sec-edgar","filing":"0001203311-22-000067","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000067/edgardoc.xml","form_type":"4"}},{"id":2118611,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2022-11-14T18:15:18.000Z","date":"2022-11-09","kind":"grant","acquired":true,"shares":275000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Options are subject to performance vesting in tranches tied to price targets for shares of the Issuer's common stock generally achievable on specified timelines on or before December 31, 2028 or an earlier change of control of the Issuer. Each such tranche will time-vest 1/3 on the date of performance vesting, 1/3 on the 9 month anniversary of performance vesting and 1/3 on the 18 month anniversary of performance vesting."}],"balance_after":275000,"derivative":{"exercise_price":137.96,"expiration_date":"2032-11-09","underlying":"Common Stock","underlying_shares":275000},"source":{"system":"sec-edgar","filing":"0000899243-22-035735","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000089924322035735/doc4.xml","form_type":"4"}},{"id":2135005,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-19T19:17:32.000Z","date":"2022-10-17","kind":"exercise","acquired":false,"shares":4607,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vested at a rate of 25% on 8/30/2019 and monthly thereafter until all the options were fully vested on 8/30/22."}],"balance_after":9403,"derivative":{"exercise_price":77.45,"expiration_date":"2028-09-07","underlying":"Common Stock","underlying_shares":4607},"source":{"system":"sec-edgar","filing":"0001203311-22-000057","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000057/edgardoc.xml","form_type":"4"}},{"id":2135004,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-19T19:17:32.000Z","date":"2022-10-17","kind":"exercise","acquired":false,"shares":3189,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Options vested at a rate of 25% on 8/30/2019 and monthly thereafter until all the options were fully vested on 8/30/22."}],"balance_after":0,"derivative":{"exercise_price":76.86,"expiration_date":"2028-08-30","underlying":"Common Stock","underlying_shares":3189},"source":{"system":"sec-edgar","filing":"0001203311-22-000057","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000057/edgardoc.xml","form_type":"4"}},{"id":2135003,"issuer":{"id":13956,"kind":"organization","name":"Seagen Inc.","symbol":"SGEN"},"owners":[{"id":45392,"kind":"person","name":"DANSEY ROGER D","position":1,"cik":"0001741836","reported_name":"DANSEY ROGER D","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO & CMO"}}],"security":"Non-Qualified Stock Option (right to buy)","published_at":"2022-10-19T19:17:32.000Z","date":"2022-10-17","kind":"exercise","acquired":false,"shares":2204,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vested at a rate of 25% on 5/21/2019 and monthly thereafter until all the options were fully vested on 5/21/22."}],"balance_after":0,"derivative":{"exercise_price":65.11,"expiration_date":"2028-06-15","underlying":"Common Stock","underlying_shares":2204},"source":{"system":"sec-edgar","filing":"0001203311-22-000057","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1060736/000120331122000057/edgardoc.xml","form_type":"4"}}],"next_cursor":"2022-10-19T19:17:32.000000Z,2135003"}